ASH 2014 | ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma
Marek Trněný
Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma, including the study design, efficacy and safety endpoints, and conclusions
Similar topics
Related videos

Venetoclax monotherapy in MCL: longer-term results
Matthew Davids

Successful use of zanubrutinib for R/R MCL in China
Yuqin Song

RB/RC induction for mantle cell lymphoma: promising pooled analysis data
Reid Merryman

VR-CAP beats R-CHOP for frontline MCL
Tadeusz Robak

Reversible BTK inhibitor ARQ 531 for CLL and NHL
Jennifer Woyach
More from Marek Trněný